<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965859</url>
  </required_header>
  <id_info>
    <org_study_id>PNA-20140110-v2</org_study_id>
    <nct_id>NCT02965859</nct_id>
  </id_info>
  <brief_title>The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Randomized,Double-blind,Double-dummy,Multiple-dose Parallel Control,Multiple Centers Study to Assess the Safety and Dose-range of Metacavir Enteric-coated Capsules for Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Yipinhong Pharmaceutical CO.,LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Yipinhong Pharmaceutical CO.,LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the safety and effectiveness of different doses of&#xD;
      Metacavir Enteric-coated Capsules in treatment of chronic hepatitis B,as well as to find an&#xD;
      appropriate clinical dosage by comparing the effect of different doses of treatment,in order&#xD;
      to provide references of clinical trial of the next phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      180 eligible subjects will be included.According to the set grouping method of dose&#xD;
      escalation.Subjects will be randomized in a 1:1:1:1 proportion of Metacavir Enteric-coated&#xD;
      Capsules(80mg/160mg/320mg) group,positive control group or placebo control group.Each group&#xD;
      has 36 subjects.&#xD;
&#xD;
      1.Subjects will use the study medication(2 hours before or after meal,once a day) from Visit&#xD;
      3 to Visit 5.&#xD;
&#xD;
        1. Metacavir Enteric-coated Capsules 80mg Group:Metacavir Enteric-coated Capsules&#xD;
           80mg,Metacavir Enteric-coated Capsules Placebo 240mg,Adefovir Dipivoxil Capsule Placebo&#xD;
           10mg;&#xD;
&#xD;
        2. Metacavir Enteric-coated Capsules 160mg Group:Metacavir Enteric-coated Capsules&#xD;
           160mg,Metacavir Enteric-coated Capsules Placebo 160mg,Adefovir Dipivoxil Capsule Placebo&#xD;
           10mg;&#xD;
&#xD;
        3. Metacavir Enteric-coated Capsules 320mg Group:Metacavir Enteric-coated Capsules&#xD;
           320mg,Adefovir Dipivoxil Capsule Placebo 10mg;&#xD;
&#xD;
        4. Positive Control(Adefovir Dipivoxil Capsule) Group:Metacavir Enteric-coated Capsules&#xD;
           Placebo 320mg,Adefovir Dipivoxil Capsule 10mg;&#xD;
&#xD;
        5. Placebo Control Group:Metacavir Enteric-coated Capsules Placebo 320mg,Adefovir Dipivoxil&#xD;
           Capsule Placebo 10mg;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in the logarithms of measurement data of HBV-DNA at Week 12 of treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change from baseline in the logarithms of measurement data of HBV-DNA at Week 12 of treatment.（Unit：log10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-chronic hepatitis B</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of subjects whose HBV-DNA are down to double logarithms at Week 12 of treatment.(Unit：%)&#xD;
The proportion of subjects whose HBV-DNA are not detected or less than upper limit of normal at Week 12 of treatment.(Unit：%)&#xD;
The proportion of subjects (HBeAg positive at baseline) whose is changed at Week 12 of treatment.(Unit：%)&#xD;
The proportion of subjects whose HBsAg is changed to negative at Week 12 of treatment.(Unit：%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events(AEs)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metacavir Enteric-coated Capsules 80mg&#xD;
Metacavir Enteric-coated Capsules Placebo 240mg&#xD;
Adefovir Dipivoxil Capsule Placebo 10mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules 160mg&#xD;
Metacavir Enteric-coated Capsules Placebo 160mg&#xD;
Adefovir Dipivoxil Capsule Placebo 10mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metacavir Enteric-coated Capsules 320mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules 320mg&#xD;
Adefovir Dipivoxil Capsule Placebo 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adefovir Dipivoxil Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules Placebo 320mg&#xD;
Adefovir Dipivoxil Capsule 10mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules Placebo 320mg&#xD;
Adefovir Dipivoxil Capsule Placebo 10mg;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules 80mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules 80mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules 160mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules 160mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules 320mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules 320mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsules 320mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules Placebo 240mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules Placebo 240mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules Placebo 160mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules Placebo 160mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules Placebo 320mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules Placebo 320mg</description>
    <arm_group_label>Adefovir Dipivoxil Capsule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil Capsule10mg</intervention_name>
    <description>Adefovir Dipivoxil Capsule10mg</description>
    <arm_group_label>Adefovir Dipivoxil Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil Capsule Placebo 10mg</intervention_name>
    <description>Adefovir Dipivoxil Capsule Placebo 10mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
    <arm_group_label>Metacavir Enteric-coated Capsules 320mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are at least 18 years of age and no older than 65;&#xD;
&#xD;
          -  Subjects,with an established clinical history of HBV at Screening,has a positive HBsAg&#xD;
             test(&gt;6months) regardless of a positive/negative HBeAg test;&#xD;
&#xD;
          -  At Screening,HBV-DNA&gt;10^5 copies/ml in HBeAg positive or HBV-DNA&gt;10^4 copies/ml in&#xD;
             HBeAg negative(HBV-DNA was evaluated by polymerase chain reaction fluorescent&#xD;
             labeling.);&#xD;
&#xD;
          -  Subjects with abnormal liver function test defined as alanine aminotransferase(ALT)&#xD;
             was 2~10 times upper limit of normal in HBeAg positive or 1.5~10 times upper limit of&#xD;
             normal in HBeAg negative;&#xD;
&#xD;
          -  Subjects who are willing to require any other treatment for anti-hepatitis B during&#xD;
             the study period;&#xD;
&#xD;
          -  Subjects who are willing to take measures for effective non-pharmaceutical&#xD;
             contraception;&#xD;
&#xD;
          -  Given their signed written informed consent to participate;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with hepatitis C(HCV),hepatitis D(HDV),autoimmune hepatitis,hereditary liver&#xD;
             disease or any other active hepatitis;&#xD;
&#xD;
          -  A positive human immunodeficiency virus(HIV) test result;&#xD;
&#xD;
          -  Subjects,who in the opinion of the investigator,have a current diagnosis of&#xD;
             hepatocellular carcinoma or serum α-fetoprotein(AFP)&gt;100ug/L;&#xD;
&#xD;
          -  Subjects with severe hepatitis or decompensated liver disease defined as hepatic&#xD;
             encephalopathy,ascites,low protein blood syndrome(albumin ≤30g/l) or variceal&#xD;
             bleeding;&#xD;
&#xD;
          -  Serum Creatinine(SCr) exceeds upper limit of normal;&#xD;
&#xD;
          -  At Screening,ALT&gt;10 times upper limit of normal,Total Bilirubin(TBIL)&gt;double upper&#xD;
             limit of normal or transient hepatic decompensation caused by condition aggravation;&#xD;
&#xD;
          -  Subjects who required treatment with nucleoside antiviral drugs such as&#xD;
             lamivudine,Adefovir dipivoxil,Telbivudine,Tenofovir disoproxil or Entecavir before&#xD;
             Screening;&#xD;
&#xD;
          -  Subjects who require treatment with interferon-α，thymosin α-1 or other antiviral&#xD;
             therapy,immunosuppressive agents,immune modulators within 6 months before Screening;&#xD;
&#xD;
          -  Subjects with cardiac disease,hematological system disease,cancer,impaired immunity or&#xD;
             psychiatric disease;&#xD;
&#xD;
          -  Hemoglobin&lt;10g/dl,white blood cell count&lt;3.5 10^9/L,platelets&lt;80 10^9/L;&#xD;
&#xD;
          -  Subjects,who in the opinion of the investigator,have a current diagnosis of&#xD;
             pancreatitis pre-dose within 24 weeks;&#xD;
&#xD;
          -  History of hypersensitivity or allergy to any of the study drugs;&#xD;
&#xD;
          -  Subjects who participate in other clinical trials within 3 months prior to Screening;&#xD;
&#xD;
          -  Women who are pregnant or lactating or planning a pregnancy recently;&#xD;
&#xD;
          -  Subjects in the opinion of the investigator,could not participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maorong Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>81 Military Hospital of China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yonggang Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing 302 Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongfeng Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanlin Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wannan Medical College Yijishan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maorong Wang</last_name>
    <phone>025-80864021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>81 Military Hospital of China</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maorong Wang</last_name>
      <phone>025-80864021</phone>
    </contact>
    <investigator>
      <last_name>Maorong Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

